July 15, 2015 - Vital Images Inc. will debut its U.S. Food and Drug Administration (FDA) 510(k)-cleared CT Myocardial Perfusion application at the 10th annual scientific meeting of the Society of Cardiovascular Computed Tomography (SCCT). The meeting will be held in Las Vegas July 16-19.
Cardiac computed tomography (CT) procedures are performed to determine the function of the heart muscle called the myocardium. Vital's CT Myocardial Perfusion application enables physicians to visualize and analyze the heart's blood flow using data collected during cardiac CT scans. It provides semi-automatic measurements, segmentation of the myocardium, calculation of perfusion results and detailed perfusion polar maps. CT Myocardial Perfusion evaluation can be combined with cardiac CT angiography (CCTA) in a single examination to assess patients with acute chest pain.
The application was developed using feedback gathered from industry experts who also participated in the CORE 320 study, led by Toshiba Medical Systems Corp. CORE 320 used Toshiba's Aquilion ONE to determine the effectiveness of 320-detector row dynamic volume CT compared to single-photon emission computed tomography (SPECT) technology. It showed that CCTA findings more closely predict whether a patient undergoes revascularization than results generated with SPECT.
For more information: www.vitalimages.com
August 17, 2026 
